EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1

K van Vliet, A M Dijkstra iD, M J Bouva, J van der Krogt, K Bijsterveld, F van der Sluijs, M G de Sain-van der Velden, K Koop, A Rossi, J A Thomas, C A Patera, M B G Kiewiet und 6 weitere

Journal of Inherited Metabolic Disease · 2023

DOI: 10.1002/jimd.12669 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2023. Verfasst von K van Vliet und 17 weiteren Autor:innen. Beteiligte Einrichtung: Section of Metabolic Diseases, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Tyrosinemias. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dried blood spot succinylacetone (SA) is often used as a biomarker for newborn screening (NBS) for tyrosinemia type 1 (TT1). However, false‐positive SA results are often observed. Elevated SA may also be due to maleylacetoacetate isomerase deficiency (MAAI‐D), which appears to be clinically insignificant. This study investigated whether urine organic acid (uOA) and quantitative urine maleic acid (Q‐uMA) analyses can distinguish between TT1 and MAAI‐D. We reevaluated/measured uOA (GC–MS) and/or Q‐uMA (LC–MS/MS) in available urine samples of nine referred newborns (2 TT1, 7 false‐positive), eight genetically confirmed MAAI‐D children, and 66 controls. Maleic acid was elevated in uOA of 5/7 false‐positive newborns and in the three available samples of confirmed MAAI‐D children, but not in TT1 patients. Q‐uMA ranged from not detectable to 1.16 mmol/mol creatinine in controls ( n = 66) and from 0.95 to 192.06 mmol/mol creatinine in false‐positive newborns and MAAI‐D children ( n = 10). MAAI‐D was genetically confirmed in 4/7 false‐positive newborns, all with elevated Q‐uMA, and rejected in the two newborns with normal Q‐uMA. No sample was available for genetic analysis of the last false‐positive infant with elevated Q‐uMA. Our study shows that MAAI‐D is a recognizable cause of false‐positive TT1 NBS results. Elevated urine maleic acid excretion seems highly effective in discriminating MAAI‐D from TT1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TyrosinemiasHumansInfant, NewbornBiomarkersChromatography, LiquidCreatinineNeonatal ScreeningTandem Mass SpectrometryMaleatescis-trans-Isomerases

Stichwörter der Autor:innen

maleic acidmaleylacetoacetate isomerase deficiencynewborn screeningsuccinylacetonetyrosinemia type 1

Substanzen

BiomarkersCreatininemaleic acidMaleatesmaleylacetoacetate isomerasecis-trans-Isomerases

Autor:innen und Institutionen

  • Section of Metabolic Diseases, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Center for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Laboratory of Metabolic diseases, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Section Metabolic Diagnostics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Pediatrics, section Metabolic Diseases, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
  • Department of Translational Medicine, Section of Pediatrics, University of Naples "Federico II", Italy.

ORCID-Profile: A M Dijkstra, M R Heiner-Fokkema

Zitieren

APA

van Vliet, K., Dijkstra, A. M., Bouva, M. J., van der Krogt, J., Bijsterveld, K., van der Sluijs, F., de Sain-van der Velden, M. G., Koop, K., Rossi, A., Thomas, J. A., Patera, C. A., Kiewiet, M. B. G., Waters, P. J., Cyr, D., Québec NTBC Study Group, Boelen, A., van Spronsen, F. J., & Heiner-Fokkema, M. R. (2023). Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12669

Vancouver

van Vliet K, Dijkstra AM, Bouva MJ, van der Krogt J, Bijsterveld K, van der Sluijs F, et al. Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1. Journal of Inherited Metabolic Disease. 2023. doi:10.1002/jimd.12669

BibTeX
@article{vanVliet2023,
  author = {van Vliet, K and Dijkstra, A M and Bouva, M J and van der Krogt, J and Bijsterveld, K and van der Sluijs, F and de Sain-van der Velden, M G and Koop, K and Rossi, A and Thomas, J A and Patera, C A and Kiewiet, M B G and Waters, P J and Cyr, D and Québec NTBC Study Group, Québec NTBC Study Group and Boelen, A and van Spronsen, F J and Heiner-Fokkema, M R},
  title = {Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2023},
  doi = {10.1002/jimd.12669}
}
Kostenlos starten →